MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,719,000
EPS
-$0.01
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
-
-250,000*
0
Cost of revenue
0
-
-65,000*
0
Research and development
1,808,000
4,747,000
4,193,000
4,270,000
General and administrative
5,222,000
4,019,000
4,197,000
6,045,000
Other income
-
-
184,000*
300,000
Loss from operations
-7,030,000
-8,766,000
-8,391,000
-10,015,000
Interest income
278,000
327,000
421,000
504,000
Interest expense
16,000
20,000
23,000
28,000
Changes in the fair value of warrants
6,000
17,000
294,000
196,000
Foreign currency transaction (loss)/gain, net
-362,000
1,628,000
-126,000
1,873,000
Benefit from research and development tax credit
119,000
95,000
474,000
446,000
Net loss before income tax
-7,005,000
-6,719,000
-7,351,000
-7,024,000
Income tax benefit
0
0
0
0
Net loss
-7,005,000
-6,719,000
-7,351,000
-7,024,000
Other comprehensive income/(loss) - foreign currency translation adjustments, net of tax
286,000
-1,748,000
87,000
-2,267,000
Total comprehensive loss
-6,719,000
-8,467,000
-7,264,000
-9,291,000
Basic EPS
-0.01
-0.01
-0.009
-0.01
Diluted EPS
-0.01
-0.01
-0.009
-0.01
Basic Average Shares
803,562,708
801,805,570
804,816,799
799,947,013
Diluted Average Shares
803,562,708
801,805,570
804,816,799
799,947,013
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$6,719,000
(15.69%↑ Y/Y)
Other comprehensive
income/(loss) - foreign...
$286,000
(-95.70%↓ Y/Y)
Net loss
-$7,005,000
(52.07%↑ Y/Y)
Net loss before
income tax
-$7,005,000
(52.07%↑ Y/Y)
Interest income
$278,000
(-52.80%↓ Y/Y)
Benefit from research
and development tax...
$119,000
(-84.03%↓ Y/Y)
Changes in the fair value
of warrants
$6,000
(105.94%↑ Y/Y)
Loss from operations
-$7,030,000
(33.04%↑ Y/Y)
Foreign currency
transaction (loss)/gain,...
-$362,000
(93.20%↑ Y/Y)
Interest expense
$16,000
(-33.33%↓ Y/Y)
General and
administrative
$5,222,000
(-4.95%↓ Y/Y)
Research and development
$1,808,000
(-66.35%↓ Y/Y)
Buy us a coffee
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)